Zafgen to Present at the Canaccord Genuity 37th Annual Growth Conference
August 02 2017 - 4:05PM
Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated
to significantly improving the health and well-being of patients
affected by metabolic diseases including type 2 diabetes and
obesity, announced today that Thomas Hughes, Ph.D., President and
Chief Executive Officer of Zafgen, will present at the Canaccord
Genuity 37th Annual Growth Conference in Boston, MA on Wednesday,
August 9, 2017 at 11:00 a.m. ET.
A live audio webcast and replay of the
presentation will be available through the Events and Presentations
page of the Investors section of the Company's website
(www.zafgen.com) for 90 days following the conclusion of the live
event.
About Zafgen
Zafgen (Nasdaq:ZFGN) is a biopharmaceutical
company dedicated to significantly improving the health and
well-being of patients affected by metabolic diseases including
type 2 diabetes and obesity. Zafgen is focused on developing novel
therapeutics that treat the underlying biological mechanisms of
metabolic diseases through the MetAP2 pathway. Zafgen has pioneered
the study of MetAP2 inhibitors in both common and rare forms of
obesity. Zafgen's lead product candidate is ZGN-1061, which is a
novel, first-in-class, twice-weekly subcutaneous injection. Zafgen
aspires to improve the lives of patients through targeted
treatments and has assembled a team accomplished in bringing
therapies to patients affected by metabolic diseases.
Media/Investor Relations Contact:
Zafgen, Inc.
Patricia Allen
Chief Financial Officer
617-648-9792
Argot Partners
Investor Relations
Laura Perry
212-600-1902
laura@argotpartners.com
Spectrum Science
Media Relations
Michelle Strier
202-587-2582
mstrier@spectrumscience.com
Zafgen (NASDAQ:ZFGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zafgen (NASDAQ:ZFGN)
Historical Stock Chart
From Apr 2023 to Apr 2024